N/A N=88 Basic Science

GLP1R Polymorphisms and Response to GLP1

Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT00588380 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2011

Primary outcome: Primary: Insulin Secretion at 150-180 Minutes. — 104; 94; 81; 92 10^-9 min^-1 — p=0.11

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: GLP-1 (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Sep 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Insulin Secretion at 150-180 Minutes.	104; 94; 81; 92; 219	0.11
SECONDARY Insulin Secretion at 210-240 Minutes	152; 133; 112; 132; 325	0.09

Summary

Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes. Furthermore GLP-1 based therapy is an important part of the therapeutic armamentarium for the treatment of type 2 diabetes. The GLP-1 receptor (GLP1R) is the principal site of action of GLP-1 and GLP-1 receptor agonists like exenatide and liraglutide. The gene coding for this receptor, GLP1R, is highly polymorphic and contains numerous non-synonymous Single Nucleotide Polymorphisms (nsSNPs) which could potentially alter response to endogenous or exogenous GLP-1 or GLP-1R agonists. Indeed there is some in vitro data to support this concept. We propose to utilize a hyperglycemic clamp to test the insulin secretory response to infused GLP-1 in healthy volunteers to determine the effect of genetic variation in GLP1R on response to GLP-1.

Eligibility Criteria

Inclusion Criteria

Aged 18-40
fasting glucose concentration of less than 95 mg/dl.

Exclusion Criteria

Individuals with a BMI 40 kg/m^2
active systemic illness
medication that can alter gastric emptying, insulin secretion & action
history of abdominal surgery (other than appendectomy or tubal ligation).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00588380). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.